Other News To Note
Wednesday, November 16, 2011
Concert Pharmaceuticals Inc., of Lexington, Mass., said it inked a research collaboration with the National Institutes of Health's Therapeutics for Rare and Neglected Diseases (TRND) program to advance the firm's deuterium-modified praziquantel program as a potential treatment for schistosomiasis, a disease caused by parasitic worms.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.